Handelsavisen
prelaunch
Companies Healthcare PRME.NS
PR
PRME.NS NSE (India) Pharmaceuticals & Medical Research

Prime Securities Ltd

$275,60
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,54 %
Op margin
18,0 %
ROE
1,1 %
Net margin
12,9 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
$3,99
Open
$3,83
Next earnings
Ex-dividend
TR 1Y
About

Prime Securities Ltd provides investment banking and brokerage services in the Indian financial market, generating revenue primarily through trading commissions, asset management fees, and advisory services.

Business. Prime Securities Ltd (PRME.NS) is an investment banking and brokerage services firm operating within the financials sector. The company generates fee-based income through its investment banking and brokerage activities. It is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY13 analysts
10 buy3 hold0 sell
Avg 12m price target7,25

Analyst recommendations

13 analysts · consensus Buy
Buy10
Hold3
Sell0
12-month price target
7,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
13 analysts · indicative
Ownership
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability
1,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PRME.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PRME.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Prime Securities Ltd (PRME.NS) is an investment banking and brokerage services firm operating within the financials sector. The company generates fee-based income through its investment banking and brokerage activities. It is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Prime Securities Ltd maintains a strong liquidity position, with cash and equivalents amounting to INR 379.6 million, representing 23.9% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The operating cash flow of INR 131.5 million supports its liquidity needs without reliance on external financing.

    The company's profitability metrics are below the industry median for investment banking and brokerage services. Return on equity (ROE) is 1.05%, and return on assets (ROA) is 0.93%, both of which are significantly lower than the sector average. This suggests that the company is underperforming in terms of asset utilization and shareholder returns.

    Revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's operations are entirely within India, and there is no indication of international expansion or cross-border revenue streams. This concentration increases exposure to domestic economic and regulatory risks.

    The company's growth trajectory is modest, with no disclosed revenue growth in the most recent period. Historical revenue data is limited, but the current revenue of INR 128.2 million suggests a stable but non-expanding business model. There are no clear indicators of future revenue acceleration or market share gains.

    Risk factors are minimal, with no immediate liquidity or dilution concerns. The company has no long-term debt, and the number of shares outstanding has not changed between basic and diluted shares, indicating no dilution pressure. However, the low ROE and ROA suggest operational inefficiencies that could pose long-term risks to profitability.

    Recent filings and transcripts do not indicate any material events or strategic shifts. The company has not disclosed any major capital-raising activities, regulatory actions, or business restructurings in the latest available documents. This suggests a stable but uneventful operational environment.

    Key takeaways
    • Prime Securities Ltd has a conservative capital structure with no long-term debt and strong liquidity.
    • The company's profitability metrics are below industry medians, indicating operational inefficiencies.
    • Revenue is concentrated in a single segment and geographic market, increasing exposure to local risks.
    • There are no immediate liquidity or dilution risks, but long-term profitability remains a concern.
    • The company has not disclosed any recent strategic or financial developments.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Net income surged 106.4% year-over-year to INR 383 million, demonstrating strong top-line and bottom-line momentum.

    Free cash flow increased 76.5% to INR 312.8 million, indicating robust cash generation capabilities for the firm.

    Cash conversion ratio of 7.97 is best-in-class compared to the cohort median of 0.24.

    Debt-to-equity ratio of 0.0 ranks in the top quartile, reflecting a conservative capital structure.

    Total assets grew 30.3% year-over-year to INR 2.3 billion, signaling significant balance sheet expansion.

    BEAR CASE · 1

    Operating margin of 18.02% is slightly below the cohort median of 18.22%, indicating average operational efficiency.

    In focus — financials by report

    Annual
    ANNUALFiled 2022-05-24
    FY 2022 · Full-year highlights

    Revenue INR 455.6M, +4,4% YoY; Operating income +131,3% YoY.

    RevenueINR 455.6M+4,4 % YoY
    Operating incomeINR 217.0M+131,3 % YoY
    Net incomeINR 169.8M+106,8 % YoY
    Free cash flowINR 40.1M−53,6 % YoY
    EPS
    Operating cash flowINR 11.9M−97,1 % YoY
    Financials
    Income statement
    RevenueINR 455.6M
    Gross profitINR 442.7M
    Operating incomeINR 217.0M
    Net incomeINR 169.8M
    Margins
    Gross margin97.2%
    Operating margin47.6%
    Net margin37.3%
    FCF margin8.8%
    Balance sheet
    Total assetsINR 1.31B
    Total liabilitiesINR 192.6M
    Total equityINR 1.11B
    Cash & equivalents
    Long-term debtINR 72.8M
    Cash flow
    Operating cash flowINR 11.9M
    CapEx-INR 19.1M
    Free cash flowINR 40.1M
    SBC
    P&L flow · revenue → net income
    Revenue INR 128.2MOperating costs INR 105.1MNet income INR 16.5M
    Highlights
    • Revenue INR 455.6M, +4,4% YoY
    • Operating income +131,3% YoY
    • Net income +106,8% YoY
    • Free cash flow −53,6% YoY
    • Net margin 37.3%

    Valuation FY

    Market price
    $275,60
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.58B
    Net cash
    $379.6M
    Current ratio
    Debt / equity
    0.0
    ROA
    0.9%
    ROE
    1.1%
    Cash conversion
    797.0%
    CapEx / revenue
    -1.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Cell & Gene Therapies
    low · llm_fanout_v2
    Gene Editing Therapies
    low · llm_fanout_v2

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)PRME 0,0% · rank #60 of 109

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries2
    EX21:053ab611fc79EX21:053ab611fc79Subsidiarie97%
    EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PRME · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +206,8 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    +118,6 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    +6,2 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +171,5 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +185,3 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    +108,9 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 44 %
    EPS
    Consensus EPS
    -0,99
    Predicted surprise
    -0,08
    Beat probability
    44 %
    Analysts
    13
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio -0,01 · as of 2026-07-07 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$4,25
    Mean$7,25
    Median$8,00
    High$11,00
    Spot$275,60
    −97.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin18,0 %Above P75
    Net Margin12,9 %Above P75
    ROE1,1 %Above median
    Capex / Rev-1,5 %Above median
    D/E0,00Above median
    Cash Conv7,97Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 3 140 000 sh11 grants11 insiders
    • Schenkein David PDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Marrazzo Jeffrey DDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • NELSEN ROBERTDirector, 10% owner · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Kelly Michael AaronDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Foster-Cheek Kaye IDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Chung WendyDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Cahill ThomasDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
    • Makhni Svetlana NiChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 800 000 @ $3,67grant · 2026-04-16
    • Reine AllanDirector, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 1 300 000 @ $4,38grant · 2026-02-26
    • LEE ANN L.Chief Technical Officer · Stock Option (right to buy) → Common StockAcquired 375 000 @ $3,34grant · 2026-02-23
    • Alenson CarmanSee Remarks · Stock Option (right to buy) → Common StockAcquired 140 000 @ $3,34grant · 2026-02-23

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Prime Securities Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$22M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$26M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$10M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$22M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$6M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Keith M. GottesdienerPresident, Chief Executive Officer, Director

    Insider activity

    Net buying3 buys · 0 sellsnet $24,9M3 insiders · last 365d
    • ARCH Venture Partners XII, LLC10% owner · Common StockBought 3 030 300 @ $3,30$10,0M · 2025-08-01
    • GV 2021 GP, L.L.C.10% owner · Common StockBought 1 500 000 @ $3,30$5,0M · 2025-08-01
    • NELSEN ROBERTDirector, 10% owner · Common StockBought 3 030 300 @ $3,30$10,0M · 2025-08-01

    Short positioning

    33.5Mshares short-3.4% vs prior
    6.74days to cover
    52.7%short of daily vol
    480fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PRME.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob44 %Surprise-0,08Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    PRMEEX21:053EX21:d30Pharmaceutical
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): -166.4%Derived (calculated)
    • Return on assets (FY 2025-12-31): -58.7%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.84xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.84xDerived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -2.9%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 53.7%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -65.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -37.9%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -32.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -2.7%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -21.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 15.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 55.3%Derived (calculated)
    • Net margin (FY 2025-12-31): -4,342.4%Derived (calculated)
    • Total assets (annual): USD 342.73MSEC XBRL filing
    • Operating cash flow (annual): USD -162.56MSEC XBRL filing
    • Revenue (annual): USD 4.63MSEC XBRL filing
    • Total operating expenses (annual): USD 212.98MSEC XBRL filing
    • Cash & equivalents (annual): USD 63.03MSEC XBRL filing
    • Capex (annual): USD 4.53MSEC XBRL filing
    • Current liabilities (annual): USD 37.45MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-08FILING8-K filing →
    2026-06-05 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
    2026-06-05INSIDERCahill Thomas acquired 75.0k sh Stock Option (right to buy) — Director
    2026-06-05INSIDERFoster-Cheek Kaye I acquired 75.0k sh Stock Option (right to buy) — Director
    2026-06-05INSIDERChung Wendy acquired 75.0k sh Stock Option (right to buy) — Director
    2026-06-05INSIDERSchenkein David P acquired 75.0k sh Stock Option (right to buy) — Director
    2026-06-05INSIDERMarrazzo Jeffrey D acquired 75.0k sh Stock Option (right to buy) — Director
    2026-06-05INSIDERNELSEN ROBERT acquired 75.0k sh Stock Option (right to buy) — Director, 10% owner
    2026-06-05INSIDERKelly Michael Aaron acquired 75.0k sh Stock Option (right to buy) — Director
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-04-23FILINGDEF 14A filing →
    2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
    2026-04-16FILING8-K filing →
    2026-04-16INSIDERMakhni Svetlana Ni acquired 800.0k sh Stock Option (right to buy) — Chief Financial Officer
    2026-03-03FILING10-K filing →
    2026-03-03FILING8-K filing →
    2026-02-26 00:00 UTCINSIDER3 insider transactions — 2026-02 3 derivative
    2026-02-26INSIDERReine Allan acquired 1.30M sh Stock Option (right to buy) — Director, Chief Executive Officer
    2026-02-23INSIDERLEE ANN L. acquired 375.0k sh Stock Option (right to buy) — Chief Technical Officer
    2026-02-23INSIDERAlenson Carman acquired 140.0k sh Stock Option (right to buy) — See Remarks
    2026-01-12FILING8-K filing →
    2025-11-07FILING10-Q filing →
    2025-11-07FILING8-K filing →
    2025-09-08FILING8-K filing →
    2025-08-07FILING10-Q filing →
    2025-08-01 00:00 UTCINSIDER55 insider transactions — 2025-08 · net buy $24.9M 52 derivative
    2025-08-01INSIDERARCH Venture Partners XII, LLC bought 3.03M sh — 10% owner ~$10.00M
    2025-08-01INSIDERGV 2021 GP, L.L.C. bought 1.50M sh — 10% owner ~$4.95M
    2025-08-01INSIDERNELSEN ROBERT bought 3.03M sh — Director, 10% owner ~$10.00M
    2025-08-01INSIDERKelly Michael Aaron acquired 9.0k sh Stock Option (right to buy) — Director
    2025-08-01INSIDERLEE ANN L. disposed of 181.0k sh Stock Option (right to buy) — Chief Technical Officer
    2025-08-01INSIDERLEE ANN L. acquired 181.0k sh Stock Option (right to buy) — Chief Technical Officer
    2025-08-01INSIDERSchenkein David P disposed of 39.1k sh Stock Option (right to buy) — Director
    2025-08-01INSIDERSchenkein David P acquired 39.1k sh Stock Option (right to buy) — Director
    2025-08-01INSIDERSchenkein David P disposed of 45.0k sh Stock Option (right to buy) — Director
    2025-08-01INSIDERSchenkein David P acquired 45.0k sh Stock Option (right to buy) — Director
    2025-08-01INSIDERNELSEN ROBERT disposed of 39.1k sh Stock Option (right to buy) — Director, 10% owner
    2025-08-01INSIDERNELSEN ROBERT acquired 39.1k sh Stock Option (right to buy) — Director, 10% owner
    Showing the 40 most recent of 46 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage